GeneCentric to Present the Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Head and Neck Cancer Patients | Business

DURHAM, NC–(BUSINESS WIRE)–March 17, 2022–

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) who may benefit from treatment beyond typical surgical resection. The presentation will be made at the annual meeting of the American Association for Cancer Research (AACR), one of the world’s largest and oldest scientific gatherings in the field of cancer research, to be held at New Orleans, Louisiana, April 8-13. , 2022. The results that will be presented are from an ongoing collaboration with Jose P. Zevallos, MD, MPH, of Washington University School of Medicine in St. Louis and Neil Hayes, MD, MPH, of the University of Tennessee Health Science Center. Center for Cancer Research to discover and develop new prognostic and/or predictive signatures and associated tests to aid in the selection of treatments for HNSCC.

Several independent retrospective data sets were used as part of the signature’s initial discovery, including those providing its initial clinical utility. Oral cavity HNSCC patients with disease without lymph nodes, who are usually treated by surgical resection without additional radiotherapy and/or chemotherapy, were identified as mesenchymal or non-mesenchymal based on the new signature based on the RNA. For nearly a quarter of mesenchymal patients, survival was 2.4 times worse compared to other non-mesenchymal patients. A future diagnostic test, based on this signature and associated clinical findings, could potentially be used to “leapfrog” patients who typically only receive surgical reduction to become candidates for the addition of radiation and/or radiation therapy. chemotherapy.

“I am delighted to present the first results of this important collaboration with my colleagues at the University of Washington School of Medicine and GeneCentric evaluating the molecular subtypes of head and neck cancer,” said Neil Hayes, MD, MPH, co-founder of GeneCentric and director of the Center for Cancer Research at the University of Tennessee Health Sciences Center. “In this study, our novel RNA-based signature identified a large population of patients who typically only undergo surgical resection based on their nodal status but have a poor prognosis, making them likely candidates for additional treatment options such as radiation therapy and/or chemotherapy. ”

The full results of the initial molecular analysis and the clinical utility of this study, as well as potential future applications, will be presented at the conference. Further demonstration of clinical utility is underway, as well as initial assay development discussions with several commercial reference laboratories.

Details regarding the presentation are provided below and will be available after the meeting at

Title: Prognostic and predictive applications of mesenchymal gene expression subtype analysis for early stage HPV(-) head and neck squamous cell carcinoma

First Author: Neil Hayes, MD, MPH, Department of Medical Oncology, University of Tennessee Health Sciences Center Cancer Research Center, Memphis, Tennessee

Abstract number: 2142

Session: Session MS.CL11.02 – Biomarkers 2

Date: April 11, 2022

Time: 3:20 p.m. to 3:35 p.m. CST

About head and neck cancer

Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide, and in the United States there were estimated to be approximately 66,000 new cases and 14,00 deaths in 2021 The overall 5-year survival for stage I-II and III-IV HNSCC is approximately 70-90% and 40-60%, respectively. HNSCC of the oral cavity is the most common head and neck cancer, accounting for one-third of cases with a majority of HPV-negative and tobacco-use-associated patients. While the treatment for HNSCC depends on multiple tumor and patient factors, the three main treatments are surgical resection, radiation therapy, and chemotherapy. Patients with early-stage lymph node tumors are usually treated with surgical resection, but treatment for those with more advanced lymph node tumors often includes radiation therapy and/or chemotherapy.

About GeneCentric

GeneCentric Therapeutics, Inc. is an RNA-based genomics solutions provider based in Durham, NC. The Company has designed its technologies to analyze the complexity of tumor and immune biology using its RNA-based Tumor and Immune Microenvironment Exploration (rT(I)ME) platform to discover and develop signatures of populations of responders to oncological therapies. GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostic companies in applications throughout the preclinical testing, clinical drug development and commercialization phases. For more information, visit or follow us on LinkedIn.

See the source version on

CONTACT: Robin Fastenau




SOURCE: GeneCentric Therapeutics, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 03/17/2022 07:55 / DISK: 03/17/2022 07:55

Copyright BusinessWire 2022.

Irene B. Bowles